Peptides for Islet Cell Transplant Support

Written by Adam Maggio | Medically reviewed by Dr. James Whitfield, DO, FACOI

Peptides like BPC-157, Thymosin Beta 4, and GLP-1 agonists can significantly improve islet cell survival and function after transplantation, enhancing long-term outcomes.

Islet cell transplantation offers a less invasive alternative to whole pancreas transplantation for individuals with type 1 diabetes, aiming to restore endogenous insulin production. You'll find that while promising, the survival and function of transplanted islets remain a significant challenge, and various peptides can provide crucial support.

Islet Cell Transplantation: A Targeted Approach

This procedure involves isolating insulin-producing islet cells from a deceased donor pancreas and infusing them into the recipient's liver. The goal is to achieve insulin independence and stabilize blood glucose levels without the need for daily insulin injections. However, a major hurdle is the high rate of islet cell loss shortly after transplantation due to inflammation, hypoxia (lack of oxygen), and immune rejection. Lifelong immunosuppression is also required. The focus of supportive therapies is to enhance islet survival and function.

Peptides Supporting Islet Cell Transplant

Several peptides are being investigated for their potential to improve outcomes in islet cell transplantation:

• BPC-157 (Body Protection Compound-157): This stable gastric pentadecapeptide is well-known for its regenerative, anti-inflammatory, and cytoprotective properties. In islet transplantation, BPC-157 can help mitigate ischemia-reperfusion injury during isolation and infusion, reduce the inflammatory response in the liver microenvironment, and protect islet cells from damage. Research by Sikiric et al. (2013) highlights its broad tissue-protective effects, which are highly relevant for delicate islet cells [1].
• Thymosin Beta 4 (TB4): As a naturally occurring peptide, TB4 promotes cell survival, angiogenesis, and tissue repair. Its anti-inflammatory and anti-apoptotic effects can help protect transplanted islets from the hostile environment of the recipient's liver and reduce early graft loss. TB4 may also support the formation of new blood vessels around the islets, improving their oxygen and nutrient supply.
• GLP-1 (Glucagon-like Peptide-1) Agonists: GLP-1 agonists, such as exenatide or liraglutide, have direct trophic effects on beta cells, promoting their proliferation and survival. Administering GLP-1 agonists post-transplant can enhance the function of the transplanted islets, improve glucose-dependent insulin secretion, and potentially reduce the amount of islet mass required for insulin independence. Studies have shown improved islet engraftment and function with GLP-1 analog use [2].
• Exendin-4: A potent GLP-1 receptor agonist, Exendin-4 has been specifically studied for its ability to protect islets from apoptosis and enhance their survival and function both in vitro and in vivo. It mimics the beneficial effects of natural GLP-1 on beta cells.
• Growth Hormone-Releasing Peptides (GHRPs): Peptides like GHRP-2 or GHRP-6 stimulate the release of growth hormone, which has anabolic and regenerative effects. This can support the overall health and recovery of the recipient, and indirectly contribute to a more favorable environment for islet survival.

Mechanisms of Islet Support

These peptides contribute to islet cell transplant success through various mechanisms:

1. Islet Protection: BPC-157, TB4, and GLP-1 agonists directly protect islet cells from inflammatory damage, oxidative stress, and apoptosis during and after transplantation.
2. Enhanced Engraftment: TB4 and GLP-1 agonists can improve the integration of islets into the recipient's liver by promoting angiogenesis and creating a more supportive microenvironment.
3. Improved Function: GLP-1 agonists enhance the glucose-sensing and insulin-secreting capabilities of the transplanted islets, leading to better glycemic control.
4. Reduced Immunogenicity: While not directly immunosuppressive, some peptides may modulate the local immune response, potentially reducing the intensity of rejection.

Consider the distinction between immunosuppressive drugs and supportive peptides. Immunosuppressants are essential to prevent the immune system from attacking the foreign islet cells. Supportive peptides, in contrast, work to enhance the intrinsic viability and function of the islets themselves, making them more resilient to the transplant process and the challenges of the new environment. You'll find that both are critical for maximizing the success of islet transplantation.

Clinical Outlook and Patient Care

The integration of peptides into islet cell transplant protocols is an exciting area of research. While GLP-1 agonists are already used in diabetes management, their specific role in islet transplant recipients is being further defined. Peptides like BPC-157 and TB4, while showing strong preclinical promise, require more extensive clinical trials to establish their standard use. The ultimate goal is to improve long-term islet survival and reduce the need for immunosuppression. You don't want to miss opportunities to improve patient outcomes.

Practical Takeaway

If you are considering or have undergone islet cell transplantation, discussing adjunctive peptide therapies with your transplant endocrinologist or surgeon is highly recommended. They'll help you explore how peptides like GLP-1 agonists (e.g., 1.2mg daily subcutaneous injection) or investigational peptides like BPC-157 (e.g., 250mcg daily) could support islet survival and function, contributing to better long-term glycemic control and reduced insulin dependence.

References

[1] Sikiric, P., Seiwerth, S., Rucman, R., Kolenc, D., Rokotov, D. S., Oršolić, N., ... & Kokot, Z. (2013). Brain-gut axis and pentadecapeptide BPC 157: Interaction with NO-system. Current Pharmaceutical Design, 19(4), 764-773.

[2] Farilla, L., et al. (2003). Glucagon-like peptide 1 promotes islet cell proliferation and inhibits apoptosis in human pancreatic islets. Endocrinology, 144(3), 871-878.